BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 27346836)

  • 1. Btg2 is a Negative Regulator of Cardiomyocyte Hypertrophy through a Decrease in Cytosolic RNA.
    Masumura Y; Higo S; Asano Y; Kato H; Yan Y; Ishino S; Tsukamoto O; Kioka H; Hayashi T; Shintani Y; Yamazaki S; Minamino T; Kitakaze M; Komuro I; Takashima S; Sakata Y
    Sci Rep; 2016 Jun; 6():28592. PubMed ID: 27346836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Btg1 and Btg2 regulate neonatal cardiomyocyte cell cycle arrest.
    Velayutham N; Calderon MU; Alfieri CM; Padula SL; van Leeuwen FN; Scheijen B; Yutzey KE
    J Mol Cell Cardiol; 2023 Jun; 179():30-41. PubMed ID: 37062247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUV39H2/KMT1B Inhibits the cardiomyocyte senescence phenotype by down-regulating BTG2/PC3.
    Wang K; Zhu QZ; Ma XT; Cheng C
    Aging (Albany NY); 2021 Sep; 13(18):22444-22458. PubMed ID: 34559682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JunD attenuates phenylephrine-mediated cardiomyocyte hypertrophy by negatively regulating AP-1 transcriptional activity.
    Hilfiker-Kleiner D; Hilfiker A; Castellazzi M; Wollert KC; Trautwein C; Schunkert H; Drexler H
    Cardiovasc Res; 2006 Jul; 71(1):108-17. PubMed ID: 16690042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy.
    Huang S; Zou X; Zhu JN; Fu YH; Lin QX; Liang YY; Deng CY; Kuang SJ; Zhang MZ; Liao YL; Zheng XL; Yu XY; Shan ZX
    J Cell Mol Med; 2015 Mar; 19(3):608-19. PubMed ID: 25583328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FAK-related nonkinase attenuates hypertrophy induced by angiotensin-II in cultured neonatal rat cardiac myocytes.
    Qin J; Liu ZX
    Acta Pharmacol Sin; 2006 Sep; 27(9):1159-64. PubMed ID: 16923336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy.
    Hingtgen SD; Tian X; Yang J; Dunlay SM; Peek AS; Wu Y; Sharma RV; Engelhardt JF; Davisson RL
    Physiol Genomics; 2006 Aug; 26(3):180-91. PubMed ID: 16670255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3.
    Li H; Gao S; Ye J; Feng X; Cai Y; Liu Z; Lu J; Li Q; Huang X; Chen S; Liu P
    Mol Cell Endocrinol; 2014 Feb; 382(2):998-1006. PubMed ID: 24291639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1.
    Feng XJ; Gao H; Gao S; Li Z; Li H; Lu J; Wang JJ; Huang XY; Liu M; Zou J; Ye JT; Liu PQ
    Br J Pharmacol; 2015 Jun; 172(11):2852-63. PubMed ID: 25625556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reciprocal regulation of miR-23a and lysophosphatidic acid receptor signaling in cardiomyocyte hypertrophy.
    Yang J; Nie Y; Wang F; Hou J; Cong X; Hu S; Chen X
    Biochim Biophys Acta; 2013 Aug; 1831(8):1386-94. PubMed ID: 23711961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor suppressor gene ING3 induces cardiomyocyte hypertrophy via inhibition of AMPK and activation of p38 MAPK signaling.
    Wang J; Liu Z; Feng X; Gao S; Xu S; Liu P
    Arch Biochem Biophys; 2014 Nov; 562():22-30. PubMed ID: 25151306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy.
    Liu L; An X; Li Z; Song Y; Li L; Zuo S; Liu N; Yang G; Wang H; Cheng X; Zhang Y; Yang X; Wang J
    Cardiovasc Res; 2016 Jul; 111(1):56-65. PubMed ID: 27084844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition.
    Coppola V; Musumeci M; Patrizii M; Cannistraci A; Addario A; Maugeri-Saccà M; Biffoni M; Francescangeli F; Cordenonsi M; Piccolo S; Memeo L; Pagliuca A; Muto G; Zeuner A; De Maria R; Bonci D
    Oncogene; 2013 Apr; 32(14):1843-53. PubMed ID: 22614007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PKCζ interacts with STAT3 and promotes its activation in cardiomyocyte hypertrophy.
    Li J; Gao H; Huang J; Wang P; Huang Y; Luo W; Zhang X; Shen P; You J; Cai S; Li Z; Liu P
    J Pharmacol Sci; 2016 Sep; 132(1):15-23. PubMed ID: 27094369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of mAKAPβ in the process of cardiomyocyte hypertrophy induced by angiotensin II.
    Guo H; Liu B; Hou L; The E; Li G; Wang D; Jie Q; Che W; Wei Y
    Int J Mol Med; 2015 May; 35(5):1159-68. PubMed ID: 25739102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of nuclear β-catenin/c-Myc axis promotes oxidative stress injury in streptozotocin-induced diabetic cardiomyopathy.
    Liu P; Su J; Song X; Wang S
    Biochem Biophys Res Commun; 2017 Dec; 493(4):1573-1580. PubMed ID: 28989026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated overexpression of diacylglycerol kinase-zeta inhibits endothelin-1-induced cardiomyocyte hypertrophy.
    Takahashi H; Takeishi Y; Seidler T; Arimoto T; Akiyama H; Hozumi Y; Koyama Y; Shishido T; Tsunoda Y; Niizeki T; Nozaki N; Abe J; Hasenfuss G; Goto K; Kubota I
    Circulation; 2005 Mar; 111(12):1510-6. PubMed ID: 15781737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3beta/mTOR signaling pathway.
    Diniz GP; Carneiro-Ramos MS; Barreto-Chaves ML
    Basic Res Cardiol; 2009 Nov; 104(6):653-67. PubMed ID: 19588183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RGS2 is upregulated by and attenuates the hypertrophic effect of alpha1-adrenergic activation in cultured ventricular myocytes.
    Zou MX; Roy AA; Zhao Q; Kirshenbaum LA; Karmazyn M; Chidiac P
    Cell Signal; 2006 Oct; 18(10):1655-63. PubMed ID: 16517124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deubiquitinating enzyme CYLD mediates pressure overload-induced cardiac maladaptive remodeling and dysfunction via downregulating Nrf2.
    Wang H; Lai Y; Mathis BJ; Wang W; Li S; Qu C; Li B; Shao L; Song H; Janicki JS; Sun SC; Wang XL; Tang D; Cui T
    J Mol Cell Cardiol; 2015 Jul; 84():143-53. PubMed ID: 25935309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.